Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib-Reference-Cited by-同舟云学术

Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib

Published:2019-10 Issue:5 Volume:43 Page:e76-e78
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Casadei Gardini Andrea,Scarpi Emanuela,Foschi Francesco Giuseppe,Marisi Giorgia,Maltoni Marco,Frassineti Giovanni Luca

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference10 articles.

1. Management and patient survival in hepatocellular carcinoma: does the physician's level of experience matter?;Chen;J Gastroenterol Hepatol,2008

2. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellularcarcinoma;Sherman;Curr Oncol,2011

3. Management of hepatocellular carcinoma:an update;Bruix;Hepatology,2011

4. Shaping the future management of hepatocellular carcinoma;Abou-Alfa;Semin Liver Dis,2013

5. eNOS polymorphisms and clinical outcome in advanced HCC atients receiving sorafenib: final results of the ePHAS study;Casadei Gardini;Oncotarget,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments;Digestive and Liver Disease;2024-02

2. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment;Clinical and Molecular Hepatology;2023-10-01

3. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population;European Journal of Cancer;2023-02

4. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy;Journal of Chemotherapy;2022-02-14

5. The Perceived Ability of Gastroenterologists, Hepatologists and Surgeons Can Bias Medical Decision Making;International Journal of Environmental Research and Public Health;2020-02-07